Statement By Dinesh Thakur Regarding US Government's Case Against Ranbaxy

  Statement By Dinesh Thakur Regarding US Government's Case Against Ranbaxy

PR Newswire

WASHINGTON, May 13, 2013

WASHINGTON, May 13, 2013 /PRNewswire-USNewswire/ -- Today, the United States
government brought to a conclusion an eight-year criminal and civil
investigation of Ranbaxy Laboratories Limited, India's largest generic drug
company, and Ranbaxy, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy
Laboratories, Inc., Ranbaxy USA, Inc., and Ohm Laboratories, Inc. ("Ranbaxy").
Ranbaxy has agreed to pay $500 million to resolve allegations of falsifying
drug data and systemic manufacturing violations. Ranbaxy USA Inc. has pleaded
guilty to multiple criminal violations. Dinesh Thakur served as the
whistleblower in this case and is the former Ranbaxy Director and Global Head,
Research Information & Portfolio Management.

Statement by Dinesh Thakur:

"I am relieved that the government's investigation has concluded. I am
thankful for the remarkable effort of United States Food and Drug
Administration, Department of Justice, United States Attorney's Office for the
District of Maryland, USAID, and State Medicaid Fraud Control Units. Their
work has been tireless and dedicated.

"Eight years ago, as the Director of Project & Information Management at
Ranbaxy, I discovered that the company falsified drug data and systemically
violated current good manufacturing practices and good laboratory practices.
Ranbaxy's management was notified of these widespread problems. When they
failed to correct the problems, it left me with no choice but to alert
healthcare authorities.

"I worked with U.S. regulatory authorities for two years to expose the fraud.
In furtherance of this effort, I filed a lawsuit to hold Ranbaxy accountable.
It took us eight years to help government authorities unravel a complicated
trail of falsified records and dangerous manufacturing practices that
threatened to compromise the quality and safety of Ranbaxy drugs. Along the
way, the government barred the importation of Ranbaxy drugs, held the company
accountable for its data fraud under FDA's Application Integrity Policy, and
required it to implement corrective measures to prevent the problems from

"As a senior pharmaceutical executive, I understand the importance of
regulatory oversight in ensuring drug quality and safety. There are unique
challenges in a global drug market, which is highly dependent on international
manufacturing and distribution. In fact, approximately 78 percent of
prescription drugs dispensed in the United States are generic, and a growing
percentage of drugs – both generic and name brand – is manufactured overseas.
This case highlights the need for effective regulation that applies to drugs
sold in the United States, regardless where they are manufactured.

I would like to thank FDA's Office of Criminal Investigation, United States
Attorney's Office for the District of Maryland, Department of Justice, USAID,
and Andrew M. Beato, Bob Muse, and Rory Kelly of Stein Mitchell Muse &
Cipollone LLP. I hope that our actions and this case have helped to improve
the quality and safety of drugs in the United States and abroad."


Please visit


For media inquiries, please contact or 202-337-0808;
for inquiries from India media,

SOURCE Dinesh Thakur

Press spacebar to pause and continue. Press esc to stop.